RxDoctor Payments DataLook up a doctor →

Jeremy Bock, MD

Interventional Cardiology · Leesburg, VANPI 1962546366

Payments from drug & device makers

$201,566in general payments, 2019–2025

Across 845 payments — averaging $238.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$152K
  • Boston Scientific$38K
  • Pfizer$959
  • Novartis$934
  • Johnson & Johnson$868
  • Abiomed$833
  • plus $8K from 47 others

What the payments were for

  • Consulting fees$72,23836%
  • Speaking & faculty fees$61,35630%
  • Travel & lodging$46,03423%
  • Food & beverage$21,73611%
  • Education$2030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$201,566 in reported general payments places this provider in the 90th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$188,694
Medicare patients
1,408
Services billed
2,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$80,214
EntrestoSacubitril/Valsartan39$58,541
JardianceEmpagliflozin16$25,486
XareltoRivaroxaban19$24,709
OzempicSemaglutide12$16,557
BrilintaTicagrelor24$14,693
ClopidogrelClopidogrel Bisulfate108$2,039
Atorvastatin Calcium91$1,267
Metoprolol Succinate83$1,199
Rosuvastatin Calcium79$1,025
Clonidine15$947
Carvedilol82$843
Losartan Potassium88$746
Valsartan19$551
Ezetimibe17$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$959$80,21454 claims
NovartisEntresto$934$58,54139 claims
Boehringer IngelheimJardiance$831$25,48616 claims
Johnson & JohnsonXarelto$868$24,70919 claims
Novo NordiskOzempic$424$16,55712 claims
AstraZenecaBrilinta$458$14,69324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →